Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb 18:5:21.
doi: 10.3389/fnins.2011.00021. eCollection 2011.

Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions

Alexandre E Medina  1
Affiliations

Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions

Alexandre E Medina. Front Neurosci. .

Abstract

Neuronal plasticity is an essential property of the brain that is impaired in different neurological conditions. Phosphodiesterase type 1 (PDE1) inhibitors can enhance levels of the second messengers cAMP/cGMP leading to the expression of neuronal plasticity-related genes, neurotrophic factors, and neuroprotective molecules. These neuronal plasticity enhancement properties make PDE1 inhibitors good candidates as therapeutic agents in many neurological conditions. However, the lack of specificity of the drugs currently available poses a challenge to the systematic evaluation of the beneficial effect of these agents. The development of more specific drugs may pave the way for the use of PDE1 inhibitors as therapeutic agents in cases of neurodevelopmental conditions such as fetal alcohol spectrum disorders and in degenerative disorders such as Alzheimer's and Parkinson's.

Keywords: Alzheimer; Parkinson; cAMP; cGMP; drug development; fetal alcohol spectrum disorders; phosphodiesterase; vinpocetine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Inhibition of phosphodiesterase type 1 (PDE1) lead to the increase of cAMP and cGMP and ultimately to the expression of plasticity-related genes. AC, adenyl cyclase; GC, guanylate cyclase; CREB, cAMP responding element binding protein; SRF, serum response factor.
Figure 2
Figure 2
Inhibition of phosphodiesterase type 1 may lead to phosphorylation of AMPA receptors and its incorporation to the synapse. AC, adenyl cyclase; GC, guanylate cyclase.
See this image and copyright information in PMC

References

    1. Atkins C. M., Selcher J. C., Petraitis J. J., Trzaskos J. M., Sweatt J. D. (1998). The MAPK cascade is required for mammalian associative learning. Nat. Neurosci. 1, 602–609 - PubMed
    1. Bagetta V., Ghiglieri V., Sgobio C., Calabresi P., Picconi B. (2010). Synaptic dysfunction in Parkinson's disease. Biochem. Soc. Trans. 38, 493–497 - PubMed
    1. Barco A., Alaarcon J. M., Kandel E. (2002). Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture. Cell 35, 345–353 - PubMed
    1. Beavo J. A. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75, 725–748 - PubMed
    1. Bereczki D., Fekete I. (2009). Vinpocetine for acute ischaemic stroke. Cochrane Database Syst. Rev. 23, CD000480 - PubMed

LinkOut - more resources